Search

everythinglearnresearchcommunity

for

Search:↓

Dermal Papilla cells are a promising tool for evaluating hair growth treatments.

The April 2014 issue of "Fertility and Sterility" discussed various reproductive health topics, including hormone therapy benefits, sperm and genetic factors in male infertility, and the link between PCOS and diabetes.

Platelet-rich plasma can help grow more and longer hair by creating new blood vessels.

The report concludes that PCOS is mainly a condition of excess male hormones and its definition may change as new information is discovered.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

Metformin helps with menstrual cycles and insulin levels in PCOS but is less effective for hair growth, diabetes prevention, and weight loss, and may improve fertility and reduce diabetes risk.

Small hormonal imbalances can cause significant health problems, so more sensitive testing for hormone-disrupting chemicals is needed.

A postmenopausal woman's excessive hair growth and hair loss were due to a non-cancerous ovarian condition, treated successfully with surgery.

Platelet-rich plasma treatment for non-scarring hair loss shows mixed results and needs more research.

Chemicals and body size might change when puberty starts and progresses, but more research is needed to confirm this.

A combination of nanomilled oral testosterone and dutasteride normalized testosterone levels in men with low testosterone and is safe for short-term use.

Leydig cells can cause testosterone-secreting adrenal tumors in women.

High levels of male hormones in women without tumors are linked to metabolic problems and can be treated with metformin.

After chemotherapy for a gestational trophoblastic tumor, normal pregnancy rates are possible, but there's a slightly higher risk of the tumor reoccurring in future pregnancies.

Finasteride doesn't affect ovulation in normal women.

The document concludes that accurate diagnosis of male and female gonadal disorders is crucial for effective treatment and better patient outcomes.

A woman was the first known case to have both polycystic ovary syndrome and autoimmune polyglandular syndrome type 2, suggesting a need to check for both conditions in similar patients.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

DHT affects hair follicle cells by changing microRNA levels, leading to less cell growth and more cell death.

The guideline suggests using specific criteria to diagnose PCOS, recommends various treatments for its symptoms, and advises screening for related health issues.

The conclusion is that metformin is a first-line treatment for PCOS, particularly for restoring ovulation and increasing pregnancy rates, with other treatments depending on specific symptoms.

Testosterone therapy can help improve sexual function, mood, and bone density in women with low androgen levels, but more research is needed on long-term safety.

Testosterone therapy may improve mood, well-being, and sexual function in premenopausal women, but more research is needed on its long-term safety and effectiveness.

Insulin resistance is linked to PCOS and can lead to other health issues, but treatments like metformin can help manage symptoms.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

Blood AMH levels are higher in women with PCOS than in those with other similar conditions.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Insulin-sensitizing drugs like metformin can help with ovulation, weight loss, and lower testosterone in some women with PCOS.

The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.